NY-FGS-GLOBAL
FGS Global announced today that it has acquired Longview Communications and Public Affairs, bringing together two of the world’s leading communications and public affairs advisory firms. FGS will now be able to serve clients more extensively throughout North America, with a deeply experienced team across eight offices in the United States and three offices in Canada. FGS’s approximately 1,300 professionals around the world offer an integrated suite of capabilities, with deep local relationships and extensive knowledge across industries and geographies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121931472/en/
Celebrating its 20th anniversary this year, Longview is the Canadian market leader, advising clients on corporate and financial communications, issues and crisis management, special situations, government relations, regulatory affairs and foreign direct investment approvals. Consistently ranked among the top 15 global PR advisors on M&A and shareholder activism, Longview advises a wide range of leading Canadian companies, as well as numerous global companies operating across the country. Its team of over 30 professionals brings extensive experience and relationships at the highest levels of government, media and business, and provides the firm’s clients an integrated service offering across disciplines that is unmatched in Canada.
Winnie Lerner, FGS’s Chief Executive Officer, North America, said, “Longview is the go-to team on all mission critical issues for companies in Canada. The firm has an outstanding track record, deep client relationships, and values aligned with our own. Extending our reach into Canada broadens our geographic footprint and enhances our ability to deliver for our clients. We have known and respected Longview for a long time, have partnered successfully on many prior client assignments and are thrilled to welcome them to FGS.”
Josh Pekarsky, Founder and Managing Partner at Longview, said, “Longview has always been about doing great work for our clients. This transaction furthers that goal and provides an exceptional platform for the future. We have been impressed by the quality and thoughtfulness of what FGS is building and are delighted to become part of this leading global platform as we embark on this next chapter of our growth. Together with FGS, we are better equipped than ever to guide our clients through an increasingly complex world and a rapidly evolving stakeholder, financial, regulatory and political environment.”
Longview has been renamed FGS Longview and will continue to be led by Longview Partners Josh Pekarsky, Bruce Drysdale, Ian Hamilton and Hugh McFadyen. FGS Longview has offices in Toronto, Vancouver and Calgary, as well as team members in Ottawa, Winnipeg, Montreal and Victoria.
Andrew Cole, FGS’s Deputy Global Chief Executive Officer, added, “FGS was created to help leaders succeed in increasingly complex stakeholder ecosystems across industries and geographies. Clients want a strategic communications and advocacy partner who can advise and execute across the inter-connected financial, media, regulatory, and employee audiences in their home country and across the globe. We’re excited to partner with the Longview team and together help clients succeed in Canada and around the world.”
About Longview
Longview is Canada’s leading corporate communications and public affairs firm, with a seasoned team of professionals working together across disciplines to serve our clients’ interests. Our strategy is simple: do good work. Longview is top ranked in Canada, and the only Canadian firm consistently ranked among the top 15 PR advisors globally, on M&A transactions and shareholder activism. Longview serves clients from seven locations across Canada. The firm’s practice areas include Corporate & Financial Communications, Public Affairs, Special Situations and Design & Branding.
About FGS Global
FGS Global is a leading global strategic communications consultancy, with approximately 1,300 professionals around the world, advising clients in navigating complex situations and reputational challenges. FGS Global was formed from the combination of Finsbury, The Glover Park Group, Hering Schuppener and Sard Verbinnen to offer board-level and c-suite counsel in all aspects of strategic communications — including corporate reputation, crisis management, government affairs and is also the leading force in financial communications worldwide. The firm is backed by WPP Plc and KKR & Co. Inc.
FGS Global offers seamless and integrated support with offices in the following locations: Abu Dhabi, Amsterdam, Beijing, Berlin, Boston, Brussels, Chicago, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, Houston, Kingston, London, Los Angeles, Munich, Paris, Riyadh, San Francisco, Shanghai, Singapore, Tokyo, Washington, D.C., South Florida, and Zurich. Its headquarters is in New York.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121931472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
